ROCHESTER, Minn. (PRWEB) September 17, 2019
Geneticure, Inc., a Rochester Minnesota company developing personalized medicine tests to improve success in chronic diseases, announces today that the U.S. Patent and Trademark Office (USPTO) and European Patent Office (EPO) have issued patents for their multi-gene combinatorial genetic algorithm to rank drug class recommendations for hypertension treatment.
The patent applies to Geneticure’s first pharmacogenomics test, in a pipeline that includes additional chronic disease panels. The Geneticure for Hypertension Pharmacogenomic Panel is the first of its kind to use multiple gene variants that have been weighted according to their impact on blood pressure response and include integration across organ systems and medication response.
The initial algorithm was formulated using a candidate-gene approach from hundreds of peer-reviewed studies that identify how subtle variations in the genetic code can influence which blood pressure medication will work most effectively, and with original research. The effectiveness of Geneticure’s assay was then assessed an optimized in multiple retrospective clinical trials that have demonstrated that a patient who is prescribed the medication ranked as the first recommendation by the algorithm had significantly lower blood pressure than a patient who did not match the recommendation.
“This is a major milestone for our company solidifying our unique cornerstones of personalized medicine: expertise in the genomics of integrative physiology, leading with powerful clinical and health economic evidence while coupled with strong intellectual property,” said Scott Snyder, co-founder and CEO of Geneticure.
About Geneticure: Geneticure Inc. is a leading personalized medicine company dedicated to the promise of using an individual’s genetics to help guide their treatment. Geneticure’s proprietary approach leverages a unique understanding for the integrative physiology in complex and chronic diseases. This allows Geneticure’s tests to be tailored for each specific disease and the underlying genetics influential to treatment response. An evidence-first company, Geneticure focuses on clinical research demonstrating improved outcomes and improved health-economics, supporting the shift from one-size-fits-all medicine to precision medicine. For more information, visit http://www.geneticure.com.